<p>Stemtech Corporation 宣布与 Lightway Ventures 建立战略合资企业，成立 Stemtech Asia (Hong Kong)，以在中国分销其干细胞营养产品。根据协议，Stemtech 将持有 51% 的股份，Lightway Ventures 持有 49%，利润平分。该合资企业旨在通过 Lightway 的区域网络在中国推广 Stemtech 的抗衰老和健康产品，重点针对主要的电子商务和药房渠道。Stemtech 计划最终在当地生产产品，初步推出预计将在上海和北京等主要城市进行，具体取决于最终的资金和监管批准。免责声明：本新闻简报由 Public Technologies (PUBT) 使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Stemtech Corp. 于 2025 年 12 月 02 日通过 ACCESS Newswire (参考 ID: 1113656) 发布了用于生成本新闻简报的原始内容，并对此信息的准确性承担全部责任。© 版权 2025 - Public Technologies (PUBT)</p>

STEK

<p>Stemtech 公司与 Lightway Ventures 成立了合资企业，进军中国市场，设立了 Stemtech Asia（香港）以分销干细胞营养产品。Stemtech 持有 51% 的股份，Lightway Ventures 持有 49% 的股份，利润均分。该合资企业瞄准主要的电子商务和药房渠道，计划在获得资金和监管批准后，在上海和北京进行本地生产和初步推广</p>

<p>Stemtech Corporation has announced a strategic joint venture with Lightway Ventures to establish Stemtech Asia (Hong Kong) for the distribution of its stem cell nutrition products in China. Under the agreement, Stemtech will hold a 51% stake and Lightway Ventures 49%, with profits split equally. The venture aims to introduce Stemtech’s anti-aging and wellness products across China, leveraging Lightway’s regional network and targeting major e-commerce and pharmacy channels. Stemtech plans to eventually manufacture products locally, with an initial rollout expected in key cities such as Shanghai and Beijing, pending final funding and regulatory approvals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stemtech Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113656) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>Stemtech Corporation 宣布与 Lightway Ventures 建立战略合资企业，成立 Stemtech Asia (Hong Kong)，以在中国分销其干细胞营养产品。根据协议，Stemtech 将持有 51% 的股份，Lightway Ventures 持有 49%，利润平分。该合资企业旨在通过 Lightway 的区域网络在中国推广 Stemtech 的抗衰老和健康产品，重点针对主要的电子商务和药房渠道。Stemtech 计划最终在当地生产产品，初步推出预计将在上海和北京等主要城市进行，具体取决于最终的资金和监管批准。免责声明：本新闻简报由 Public Technologies (PUBT) 使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Stemtech Corp. 于 2025 年 12 月 02 日通过 ACCESS Newswire (参考 ID: 1113656) 发布了用于生成本新闻简报的原始内容，并对此信息的准确性承担全部责任。© 版权 2025 - Public Technologies (PUBT)</p>
</div>

Stemtech 公司与 Lightway Ventures 成立合资企业以进军中国市场